Veea Inc. Announces Proposed Business Combination with NovaGen

What Happened

• On September 14, 2026, Veea Inc. (VEEA) announced it signed a non‑binding term sheet with NovaGen Group B.V., a personalized regenerative medicine and longevity company headquartered in Amsterdam, for a proposed business combination.
• The parties say the deal would launch "NovaGen Health Networks," a global connected health platform combining Veea’s HealthLynx platform (edge-cloud computing, connectivity and cybersecurity) with NovaGen’s cellular reprogramming science and clinical services. They are targeting execution of a definitive agreement within the coming weeks.

Key Details

• Agreement type: Non‑binding term sheet announced Sept 14, 2026; definitive agreements not yet signed.
• Integration: Veea’s HealthLynx (edge-cloud, connectivity, cybersecurity) + NovaGen’s cellular reprogramming and clinical services → NovaGen Health Networks.
• Conditions: Transaction requires completion of due diligence (including IP and valuation), definitive agreements, shareholder and regulatory approvals, and other customary closing conditions.
• Disclosure: Joint press release attached as Exhibit 99.1 to the 8-K; filing includes standard forward‑looking statement caution that the transaction may not be completed or may change.

Why It Matters

• For investors, this is a strategic partnership/possible merger that would pivot Veea toward healthcare and life‑sciences applications by pairing its connectivity and edge-cloud technology with NovaGen’s regenerative medicine capabilities.
• The announcement is preliminary and non‑binding; significant risks and approvals remain. Investors should treat this as an early-stage deal announcement and watch for a definitive agreement, material financial terms, and regulatory or shareholder filings before assuming any transaction certainty.